The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy (Q38888796)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

2

object named as

Andrew V Schally

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

4

object named as

Norman L Block

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

E David Crawford

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jehonathan H Pinthus

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Ferenc G Rick

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Marc B Garnick

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Robert H Eckel

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Thomas E Keane

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Neal D Shore

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

David N Dahdal

10

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Thomas J R Beveridge

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Dennis C Marshall

12

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

publication date

18 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

183-191

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

De novo biosynthesis of FSH like peptide by the human prostate

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Immunocytochemical localization of follicle stimulating hormone in normal human stomach

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Prostate—an extrapituitary source of follicle-stimulating hormone (FSH): Occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via Nrf2 and HIF1α signaling in human epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Role of vascular endothelial growth factor in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Regulation of vascular endothelial growth factor in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Effects of LHRH-analogues on mitogenic signal transduction in cancer cells

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Potential role of follicle‐stimulating hormone (FSH) and transforming growth factor (TGFβ1) in the regulation of ovarian angiogenesis

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to fol

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca(2 )/CREB pathway

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Follicle-stimulating hormone, interleukin-1, and bone density in adult women

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Peptide analogs in the therapy of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Hypothalamic hormones and cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone‐releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Lipoprotein lipase: from gene to obesity

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Signaling through FSH receptors on human umbilical vein endothelial cells promotes angiogenesis

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Structure-dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Role of serum FSH measurement on bone resorption in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

The relationship between gonadotrophins, gonadal hormones and bone mass in men.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Emerging therapeutic opportunities for skeletal restoration

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Follicle-stimulating hormone promotes RANK expression on human monocytes

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Bone homeostasis

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Pathogenesis of osteoblastic bone metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Morphometric evidence for bone resorption and replacement in prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgen deprivation therapy: past, present and future

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Cognitive effects of hormone therapy in men with prostate cancer: a review

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

An association of elevated serum gonadotropin concentrations and Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Effects of testosterone on cognitive and brain aging in elderly men.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Free testosterone and risk for Alzheimer disease in older men

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgens selectively protect against apoptosis in hippocampal neurones

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgens modulate neuronal vulnerability to kainate lesion

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Protective actions of sex steroid hormones in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Androgens regulate neprilysin expression: role in reducing beta-amyloid levels.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Low free testosterone is an independent risk factor for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Effects of the LHRH antagonist Cetrorelix on the brain function in mice

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2017.01.025

7 January 2021

Identifiers

10.1016/J.UROLONC.2017.01.025

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38888796&oldid=1794061379"